• Opinion
• [Reporter's View] Non-face-to-face treatment pilot project
• by Lee, Jeong-Hwan Dec 4, 2023 05:12am

• Policy
• Preferential pricing plan will be further discussed by HIPDC
• by Lee, Tak-Sun Dec 4, 2023 05:12am

• Company
• Pharma companies fiercely compete to develop ADC drugs
• by Son, Hyung-Min Dec 1, 2023 05:35am

• Policy
• Novavax’s COVID-19 vaccine receives EUA in KOR
• by Lee, Hye-Kyung Dec 1, 2023 05:35am

• Company
• AstraZeneca appoints Sewhan Chon as new Country President
• by Eo, Yun-Ho Dec 1, 2023 05:35am

• Policy
• Imfinzi's 3-drug combo burden reduced despite nonreimb
• by Lee, Tak-Sun Nov 30, 2023 05:55am

• Company
• Demand for ADC Enhertu rise despite nonreimbursement
• by Kim, Jin-Gu Nov 30, 2023 05:55am

• Policy
• External ref price reevals will be carried out as planned
• by Lee, Tak-Sun Nov 30, 2023 05:55am

• Policy
• BeiGene applies for reimb of its 2nd new drug after Brukinsa
• by Lee, Tak-Sun Nov 29, 2023 05:50am

• Company
• Samsung Biologics’ CMO orders exceed KRW 3 trillion this yr
• by Chon, Seung-Hyun Nov 29, 2023 05:50am